


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:


Listing of claims:

1. (canceled)
2. (New) A compound selected from the group consisting of:


3-methyl-4,6-dioxo-5-phenylhexahydropyrimidine-5-acetic Acid, Adamantanemethyl Ester




3-methyl-4,6-dioxo-5 phenylhexahydropyrimidine-5-acetic Acid, Cyclohexyl Ester



3-methyl-4,6-dioxo-5- δ^2 -cyclopentylhexahydropyrimidine-5-acetic Acid Adamantanemethyl Ester




3-methyl-4,6-dioxo-5- δ^2 -cyclopentylhexahydropyrimidine-5-acetic Acid Cyclohexyl Ester




, and pharmaceutically acceptable salts thereof.

3. (New) A compound selected from the group consisting of:


3-methyl-4,6-dioxo-5-phenylhexahydropyrimidine-5-acetic Acid, Neopentyl Ester




3-methyl-4,6-dioxo-5-phenylhexahydropyrimidine-5-acetic Acid Isobutyl Ester



3-methyl-4,6-dioxo-5-δ²-cyclopentylhexahydropyrimidine-5-acetic Acid Neopentyl Ester




3-methyl-4,6-dioxo-5-δ²-cyclopentylhexahydropyrimidine-5-acetic Acid Isobutyl Ester




, and pharmaceutically acceptable salts thereof.

4. (New) A compound selected from the group consisting of:

4,6-dioxo-5-allyl-5-isopentylhexahydropyrimidine-3-aceticacid, Ethyl Ester



3-ethoxycarbonyl-4,6-dioxo-5-allyl-5-isopentylhexahydropyrimidine



, and pharmaceutically acceptable salts thereof.

6. (new) A composition comprising the compound according to claim 2 and a pharmaceutically acceptable carrier or diluent.
7. (new) A composition comprising the compound according to claim 3 and a pharmaceutically acceptable carrier or diluent.
8. (new) A composition comprising the compound according to claim 4 and a pharmaceutically acceptable carrier or diluent.